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Abstract:  Lipid  nanocapsules  (LNC)  based  on  a  core-shell  structure  consisting  of  an  
oil-filled core with a surrounding polymer layer are known to be promising vehicles for the 
delivery of hydrophobic drugs in the new therapeutic strategies in anti-cancer treatments. 
The present work has been designed as basic research about different LNC systems. We 
have synthesized—and physico-chemically characterized—three different LNC systems in 
which  the  core  was  constituted  by  olive  oil  and  the  shell  by  different  phospholipids  
(phosphatidyl-serine or lecithin) and other biocompatible molecules such as Pluronic
® F68 
or chitosan. It is notable that the olive-oil-phosphatidyl-serine LCN is a novel formulation 
presented in this work and was designed to generate an enriched carboxylic surface. This 
carboxylic layer is meant to link specific antibodies, which could facilitate the specific 
nanocapsule uptake by cancer cells. This is why nanoparticles with phosphatidyl-serine in 
their shell have also been used in this work to form immuno-nanocapsules containing a 
polyclonal IgG against a model antigen (C-reactive protein) covalently bounded by means of 
a simple and reproducible carbodiimide method. An immunological study was made to 
verify that these IgG-LNC complexes showed the expected specific immune response. Finally, 
a preliminary in vitro study was performed by culturing a breast-carcinoma cell line (MCF-7) 
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with Nile-Red-loaded LNC. We found that these cancer cells take up the fluorescent Nile-
Red molecule in a process dependent on the surface properties of the nanocarriers.  
Keywords: nanocarriers; lipid nanocapsules; immuno-nanocapsules; drug delivery 
 
1. Introduction 
Nanomedicine, an emerging new field created by the fusion of nanotechnology and medicine, has 
become one of the most promising pathways for developing effective targeted therapies with particular 
impact on oncology. This is because these new therapeutic strategies could supply the tools necessary 
to improve inherent limitations of classical pharmacotherapy [1–4]. In recent years, different colloidal 
systems  such  as  nanoparticles  and  nanocapsules  have  been  reported  as  potential  carriers  for  drug 
delivery [5,6]. Structured nanocapsules are generally described as colloidal systems with a core-shell 
structure [1,2], where the core acts as a liquid reservoir for several molecules or drugs, and the shell as 
a  protective  membrane.  These  nanosystems  present  promising  applications  as  carriers  of  drugs, 
proteins or DNA chains, or in diagnosis applications as contrast agents [7,8]. Their useful properties 
include biocompatibility and biodegradability, low toxicity, controlled release of drugs and the ability 
to target specific tissues [5]. In particular, lipid nanocapsules (LNC), consisting of an oil-filled core 
with a surrounding polymer shell have special use for encapsulating and delivering hydrophobic drugs. 
The versatility of these LNC for an efficient encapsulation in their oily core of several anti-cancer 
drugs  has  been  previously  demonstrated  [9,10].  It  should  be  noted  that,  due  to  the  hydrophobic 
character  of  many  of  these  drugs,  current  pharmacotherapy  must  use  solubilizer  agents  for  their 
intravenous administration [11], which in turn is another foreign substance that has to be added in the 
blood stream. This is why LNC offer a promising system and an excellent alternative to emulsions or 
microemulsions for pharmaceutical application of hydrophobic drugs [7,12,13]. Thanks to the drug 
protection and their controlled release on cancer cells, these kinds of nanoparticles provide an ideal 
solution, leading to selective cytotoxicity, minimizing the serious and unpleasant side effects of cancer 
drugs and preventing damage to healthy tissues [14,15]. 
The shell of LNC can be formed by a wide variety of polymers/surfactants with hydrophilic segments 
such  as  polyethylene  glycol  (PEG),  polyethylene  oxide,  poloxamers,  poloxamines,  polysorbates, 
chitosan, etc. [16–19]. These types of polymers, in addition to enhancing the intrinsic colloidal stability 
of the system, may help to avoid their recognition by the mononuclear phagocyte system (MPS),  
a major drawback that often arises after intravenous injection of drug carriers, causing a decrease  
in circulating LNC as well as undesirable accumulation of these colloids in the liver or the spleen. 
Therefore, the nature of the polymeric shell is crucial to minimize the MPS action by repelling plasma 
proteins [16] and achieving the so-called Stealth
® nanosystems [5,11,20–22]. This would increase the 
in vivo long-term stability of the nanoparticles, and it would also facilitate their ability to cross certain 
biological barriers. For example, nanoparticles coated  with polysorbates  or  poloxamers  have  been 
reported to successfully pass the blood-brain-barrier and other physiological barriers [23]. 
On the other hand, although LNC represent an important class of nanocarriers capable of efficiently 
encapsulating and delivering a variety of drugs, their typical pathway to act on cancer tissues is through Int. J. Mol. Sci. 2012, 13                     
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the so-called enhanced permeability and retention effect. This means passive targeting with non-specific 
delivery  and  the  inability  to  cross  several  biological  barriers  based  on  molecular  recognition  
processes [7,10,15]. Thus, it would be advisable to improve the efficacy of chemotherapy as well as to 
decrease the systemic toxicity of these drugs by using tailor-made tumor-targeted drug carriers, thereby 
reducing—although not completely avoiding—unspecific passive delivery. Vectorization and targeting 
capacities of these systems can be implemented by surface modification with specific biomolecules 
(e.g., antibody fragments, folic acid) conjugated to LNC and enhancing the cell-targeting through 
molecular recognition processes such as ligand-receptor or antigen-antibody reactions [6,10,24–26]. 
Today, it is possible to form a LNC surface with several agents bearing diverse functional groups 
capable of covalently binding a variety of biochemically active groups. Shell polymers are generally 
synthesized with pendant functional groups such as hydroxyl, carboxyl, amine or thiol groups (–OH,  
–COOH, –NH2, or –SH). As a result, these tailored-LNCs would deliver a given drug specifically 
towards a targeted malignant tumor [4]. 
Within  this  scenario,  the  main  objective  of  the  present  work  focuses  on  developing  a  simple, 
reproducible and non-expensive procedure to synthesize LNCs systems, paying special attention to 
designing nanocapsules in which antibody molecules can be covalently attached on the surface. Thus, 
several lipidic nanosystems with different surface characteristics have been obtained and analyzed in 
order  to  acquire  a  fuller  knowledge  concerning  the  physicochemical  properties  of  these  colloidal 
particles, closely examining the role played by the components. Thus, a thorough characterization was 
made, including size, electrokinetic behavior, and colloidal stability. Specifically, we have synthesized 
three different core-shell lipid nanosystems by using a simple process with commercially available 
biocompatible components. In all cases, the hydrophobic core was constituted by olive oil, while the 
hydrophilic shell nature was varied by adding different molecules in order to generate different (and 
desirable) surface properties. The molecules used in the surface modification were phospholipidic 
molecules,  a  poloxamer,  and  chitosan.  Thus,  we  have  two  typical  reference  systems  previously 
reported [18] with an anionic and a cationic surface charge respectively, and a novel nanosystem  
(not described in the literature yet) in which the shell was constituted by phosphatidyl-serine and  
a  poloxamer  producing  a  carboxyl-functionalized  nanosystem.  In  the  second  step,  we  developed  
the chemical immobilization of a classical polyclonal IgG antibody on the carboxylated nanocapsules by 
means  of  a  reproducible  and  simple  method.  For  this,  a  well-established  procedure  based  on  the 
carbodiimide (CDI) method was used [27–30]. All the antibody-LNC systems were physico-chemically 
characterized  and  compared  with  bare  LNC.  The  immunological  response  of  our  colloidal  
immune-nanocapsules was also quantified against the specific ligand of the antibody molecules, the  
C-reactive  protein  (CRP).  The  goal  of  this  part  was  to  check  whether  this  new  LNC  system  
enriched by phosphatidyl-serine could efficiently link antibodies for future vectorization purposes, and 
whether these antibodies kept their intrinsic immuno-reactivity once they were immobilized on the 
LNC surface. 
The work finishes with an in vitro study to evaluate the potential use of our LNC. In this last  
part, Nile-Red-loaded lipid nanocapsules were prepared to make a quantitative study of particle uptake 
by  a  breast-carcinoma  cell  line  (MCF-7),  Nile-Red  being  a  commercially  available  hydrophobic 
fluorescent molecule. Int. J. Mol. Sci. 2012, 13                     
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2. Results and Discussions 
The first part of this work includes a complete physicochemical and morphological characterization 
of our colloidal systems. Their synthesis procedures are shown in experimental section. The shell of 
the simplest system (referred to as EPI) was constituted by a commercial mixture of phospholipid 
molecules (Epikuron) and a poloxamer (Pluronic
® F68), both acting as colloidal stabilizers. A second 
system  (referred  to  as  CS)  was  formulated  by  substituting  the  poloxamer  by  chitosan  oligomers. 
Finally, in the third formulation Epikuron was substituted by phosphatidyl-serine (referred to as pHS). 
Particle  size  and  size  distribution  are  key  variables  to  determine  the  in  vivo  distribution  of  the 
nanoparticles, the drug release, the targeting ability, and their colloidal stability [31,32]. Generally, a 
sub-micron size is recommended in the literature. It is advisable to formulate nanoparticles with an 
optimal size depending on their specific use, normally under 200–300 nm of diameter, and preserving, 
at the same time, the colloidal stability of the system [16]. In our case, the synthesis procedure yielded 
to spherical nanocapsules with an average diameter in the nanometric scale, Table 1. It should be noted 
that the size of all the formulations remained at a constant value under the storage conditions (pure 
water, 4 °C ) for at least four months, which is a good indication of their intrinsic stability in water. The 
morphology of the nanocarriers was analyzed by TEM. The three LNC systems showed a spherical 
shape and a size consistent with the values previously found using light back-scattering measurements. 
Figure 1 shows a TEM micrograph of the EPI nanocapsules. 
Table 1. Particle size of the different lipid nanocapsule and immuno-nanocapsule systems. 
Nanosystem  Diameter (nm) 
EPI  170 ±  20 
CS  340 ±  30 
PhS  210 ±  20 
PhS-1 mgIgG/m
2  200 ± 20 
PhS-2.5 mgIgG/m
2  204 ± 14 
Figure 1. Transmission electron microscopy photography of the EPI nanocapsules. 
 
Given the size differences among the EPI and PhS nanoparticles, the ―epikuron-poloxamer‖ pair 
appears to be a better emulsifier than the ―PhS-poloxamer‖ one, in that the former produces particles Int. J. Mol. Sci. 2012, 13                     
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with a smaller diameter than the latter. Previous results have shown that the presence of poloxamer 
together with lecithin increases the particle size in comparison to the case in which lecithin was the only 
component of the shell [18]. This feature could be extrapolated to the PhS nanoparticles (with a larger 
diameters)  suggesting  a  greater  incorporation  of  poloxamer  when  this  surfactant  is  added  together  
with  phosphatidyl-serine,  producing  nanoparticles  with  a  larger  diameter.  Results  of  electrokinetic 
measurements  and  colloidal  stability  (shown  in  the  following  sections)  appear  to  support  this  idea. 
Nevertheless,  the  most  significant  result  was  the  size  increment  found  when  chitosan  was  added 
together with epikuron. In this case, positive chitosan chains can interact electrostatically with negative 
phospholipid molecules, reducing the effective concentration of this latter emulsifier and, consequently, 
producing larger nanocapsules [18]. 
With  regard  to  the  immuno-nanocapsules,  we  will  firstly  explain  why  our  PhS-LNCs  were 
sensitized with a partial coating of IgG. It is well known that the presence of polyclonal IgG molecules 
linked onto colloidal particles causes a significant alteration of their surface properties, changing the 
electrokinetic  behavior  and  reducing  significantly  the  colloidal  stability  at  neutral  pH  [28].  The 
development of colloidally stable nanosystems is a prerequisite for successful future applications of 
drug carriers in biological media. Taking into account that a low stability has been found working with 
other nanoparticles of similar size as ours when their surfaces were saturated with IgG molecules  
(5 mgIgG/m
2) [33], we developed systems with a low to medium IgG coverage: 1 mgIgG/m
2, and  
2.5 mgIgG/m
2. The covalent coupling was developed by means of the CDI method, described in detail 
in  the  experimental  section,  and  no  aggregation  was  noted  over  the  experimental  period.  After 
coupling, immuno-nanocapsules were separated from unbound protein by a dialysis procedure. An 
analysis of the eluted solution volume from dialysis by means of spectrophotometric measurements did 
not detect any presence of protein molecules in the solution, which would indicate very high coupling 
efficiency. The size of these antibody-nanocapsule complexes (at pH 8 and low-ionic-strength medium) 
is shown in Table 1. Diameters remain similar to those of the original PhS-system regardless of the 
antibody amount on the surface. This is a good indication that the appropriate selection was made with 
our antibody density values, since an increase in the hydrodynamic diameter has been reported for 
several nanosystems having a high density of antibodies immobilized on them, meaning low stability 
and a strong tendency to aggregate [25,34]. 
Prior any further physico-chemical characterization of the immuno-complexes, it was necessary  
to  test  whether  the  immobilized  IgG  maintained  its  antigenic  activity.  Previous  results  working  
with  hard  nanospheres  in  which  IgG  was  covalently  linked  with  the  CDI  method  showed  good 
immuno-activity [27,28]. However, we are now working with soft liquid particles where IgG might 
denature when located in the oil/water interface and/or may change the preferential orientation of the 
adhered  IgG  molecule—especially  when  surfactant  molecules  (e.g.,  poloxamer)  are  placed  on  the 
surface [35]. Therefore, we quantified the immuno-reactivity by spectrophotometrically measuring the 
agglutination  extent  when  our  immuno-nanocapsules  were  mixed  with  the  corresponding  antigen 
(CRP). These experiments are determinant to test the feasibility and potential applicability of these soft 
lipid immuno-nanocapsules in future active targeting strategies. Figure 2 shows the changes in the 
optical absorbance vs. the CRP concentration for both immuno-complexes. It should be noted that at 
low CRP concentrations, those particles with a higher IgG coating were more reactive, while at [CRP] 
<5 μg/mL the highest increment of absorbance was found with the 1 mgIgG/m
2 complex. Nevertheless, Int. J. Mol. Sci. 2012, 13                     
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the immuno-agglutination extent was significant in both cases and it indicates an adequate surface 
disposition of the antibody molecules for specific recognition. 
Figure 2. Absorbance change after 300 s (λ = 570 nm) due to aggregation induced by different 
C-reactive protein (CRP) concentrations: (○) PhS-1 mgIgG/m
2; (□) PhS-2.5 mgIgG/m
2. 
Reaction medium: 13 mM borate (pH 8.0), 150 mM NaCl, 1 mg/mL NaN3, 1 mg/mL BSA. 
The starting point of optical absorbance for all experiments was 0.5. 
 
The next set of experiments was focused on determining the electrical state of the nanocapsules at 
different pH values. A magnitude commonly used to gain information about the surface state of charge 
of colloidal particles is electrophoretic mobility (μe). This is an experimental parameter directly related 
with the zeta potential existing in the shear plane of the particles [28,36]. The electrophoretic mobility 
data, gathered from low-ionic-strength media, are shown in Figure 3. The μe values depend on the 
electrical potential at the shear plane, which is ultimately governed by the composition of the LNC 
surface and by the salinity and pH conditions of the medium in which the particles are dispersed. The 
μe results agree with the nature of the shell of our nanocapsules and they confirm the presence of the 
different molecules used in their synthesis. That is, the EPI and PhS nanocapsules showed typical 
behavior of colloids with weak acid groups, giving lower μe values at acidic pH values than those 
found at neutral and basic pH. In addition, Figure 3 shows a peculiar nuance related with the nature of 
the surface-charged groups. These groups come exclusively from the Epikuron molecules in the EPI 
nanocapsules, in which phosphatidyl-choline is the major component. Thus, the phosphatidic acid—with 
a pKa between 3 and 4—is the main charged group in these LNC. However, the PhS-nanoparticles present 
only phosphatidyl-serine as phospholipidic molecules; that is, in this case there are two different surface 
charged groups: phosphatidic and carboxylic (pKa = 4.8). This is also reflected in the electrokinetic 
behavior, since the reduction in the mobility value begins at pH 5 for the PhS system while it is at pH 4 
for the EPI particles (see Figure 3). This subtle difference in our experimental μe measurements agrees 
with  other  data  gathered  with  similar  colloidal  systems  formed  by  both  phosphatidic  [18]  and 
carboxylic [37] surface groups. The presence of Pluronic
® F68 molecules on the surface does not alter 
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the electrical state of the surface, since this poloxamer is a non-ionic surfactant [18,35]. However, a μe 
reduction (in absolute value) could be expected after the incorporation of this non-ionic surfactant onto 
the  nanoparticle  surface,  since  the  presence  of  polyethylene  oxide  (PEO)  chains  would  cause  an 
outward shift of the shear plane where the ζ-potential is defined, and this would subsequently diminish 
the electrophoretic mobility. At least for polystyrene or polylactic-co-glycolic acid particles the μe 
reduction was significant and directly related to the poloxamer coating [35,38]. The results shown in 
Figure 3 for both EPI and PhS systems would indicate a higher incorporation of poloxamer for the PhS 
nanoparticles with an appreciable decrease of the absolute μe values throughout the pH range studied, 
as experimentally observed. As will be shown, the stability experiments corroborate this assumption 
related to the higher incorporation of Pluronic
® F68 in the PhS-LNC. 
Figure 3. Electrophoretic mobility vs. pH for (∆) EPI; (□) CS; and (○) PhS nanocapsules. 
On the other hand, the μe behavior of the CS nanocapsules becomes radically different. These  
CS-LNC show mobility data very similar to those found with pure chitosan nanogels [39] and they 
practically  coincide  with  previously  results  found  for  similar  chitosan  nanocapsules  [18].  The  μe 
confirms that the incorporation of chitosan was clearly effective when this polysaccharide was added 
to the formulation. It can be seen that mobility goes from positive values at acidic pH to large negative 
values  at  more  basic  pH,  presenting  an  isoelectric  point  (i.e.p.)  at  pH  7.  The  positive  charge  of 
nanocapsules is provided by the glucosamine groups of chitosan, which present a weak basic character. 
At basic pH, chitosan chains are uncharged, so that the negative μe comes from the lecithin phosphatidic 
groups. This μe behavior indicates a clear incorporation of this polycationic polymer into the nanocapsule 
shell yielding to a surface structure practically formed (in its outer part) by a chitosan layer. 
Usually, the presence of IgG molecules on the surface of colloidal particles causes a significant 
alteration of the μe values in comparison with the same bare surfaces. Therefore, the electrokinetic 
behavior of our immuno-nanocapsules can also be useful to determine the presence of such active Int. J. Mol. Sci. 2012, 13                     
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material (IgG) linked on the LNC surface. Figure 4 shows the mobility of our immuno-nanocapsules as 
a function of the medium pH. These data support the presence of antibody molecules in the particle 
surface. Also, a clear correlation is found between the mobility data and the amount of surface protein. 
It is known that, when colloidal particles are coated by a protein, the original isoelectric point of bare 
particles moves towards the isoelectric point of the pure protein. In the case of our immuno-capsules, 
they inverted the original PhS-LNC μe sign at acidic pH 4 (due to the positive electrical charge of IgG 
molecules at these pH values [28,37,40]), shifting the isoelectric points of the complexes at pH 4.6 and 
5.1 for the 1 mgIgG/m
2and 2.5 mgIgG/m
2 systems, respectively [41,42]. On the other hand, analyzing 
the μe values at neutral and basic pH, we found another important difference among bare nanocapsules 
and immuno-nanocapsules, with a clear μe decrease (in absolute value) when the antibody coating 
increased.  In  these  conditions,  the  surface  charge  density  of  the  surface  protein  layer  became 
significantly low, which translated as a reduction of the original negative surface electrostatic potential. 
It is worth remembering that μe values are usually indicative of the colloidal stability of the particles. 
Therefore, a reduction in μe values at neutral and basic pH values would imply decreased colloidal 
stability. As shown below, these complexes present low colloidal stability at physiological pH. 
Figure  4.  Electrophoretic  mobility  vs.  pH  for  (■)  PhS;  (○)  PhS-1  mgIgG/m
2;  and  
(∆) PhS-2.5 mgIgG/m
2 IgG. 
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In  the  next  set  of  experiments,  the  colloidal  stability  was  studied  at  a  pH  value  whi ch  matched   
that  of  culture  media  (7.4)  used  in  the  in vitro experiments in order to analyze the stability/instability 
of the nanocapsules when incubated with cells. Aggregations were induced by salinity using NaCl and 
CaCl2 independently. The corresponding CCC and CSC values for all the systems–nanocapsules and 
immuno-nanocapsules—are shown in Table 2. With regard to the CCC data, calcium exerts a much 
higher destabilizing effect than does sodium, as expected. This is due to the double valence of calcium, 
which screens the nanocapsule surface charge much better than sodium does. Consequently, the CCC 
values are consistently lower for CaCl2 than for NaCl. Int. J. Mol. Sci. 2012, 13                     
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Table 2. Critical coagulation concentration (CCC) and critical stabilization concentration 
(CSC) data (in mM units), at pH 7.4, using NaCl and CaCl2 as aggregating salts. 
pH 7.4 
EPI  CS  PhS 
PhS-IgG  
(1 mgm-2) 
PhS-IgG 
(2.5 mgm-2) 
CCC  CSC  CCC  CSC  CCC  CSC  CCC  CSC  CCC  CSC 
NaCl  stable  stable  aggreg  161  stable  stable  stable  stable  38  56 
CaCl2  61  77  aggreg  14  stable  stable  12  22  9  12 
Next, we examine the results found for bare nanocapsules. The CCC and CSC data gathered for  
the EPI nanocapsules are similar to those previously obtained for nanocapsules formulated with the 
same shell composition [18]. The incorporation of poloxamer into the shell confers a more hydrophilic 
character ascribed to the PEO fragments. The CSC data corresponding to CaCl2 confirm the presence 
of poloxamer molecules on the surface, showing a restabilization process typical of surfaces with 
hydrophilic character. This stability observed at moderate and high ionic strengths is governed by 
repulsive hydration forces that are explained in detail in references [43,44]. With regard to the NaCl, 
the EPI sample became completely stable in the entire NaCl-concentration range. This is due to the 
fact  that  the  CCC  is  higher  than  the  CSC,  overlapping  both  critical  concentrations  in  this  highly 
hydrophilic system. That is, the restabilization mechanism based on hydration forces begins to act  
at a salt concentration in which the classical DLVO potential barrier still has not been definitively 
eliminated by the screening effect of the electrolyte concentration [18]. 
When we analyzed the colloidal stability of PhS nanocapsules, a completely stable system was found, 
since it was impossible to coagulate at any NaCl or CaCl2 salt concentration. This feature, characteristic 
of sterically stabilized colloids, clearly indicates a higher incorporation of Pluronic
® F68 molecules into 
the PhS system in contrast to the EPI case. Furthermore, this result agrees with previous electrokinetic 
data, in which a reduction in μe values has been related to the incorporation of PEO chains on the 
surface shell, which (consequently) shifted the shear plane where the zeta potential is defined outward. 
Performing the experimental study of the stability of the CS system was a difficult task, because 
these LNC coagulated—even before adding any salt concentration—as soon as the nanocapsules were 
immersed in the buffer at pH 7.4. This high instability at neutral pH is consistent with the isoelectric 
point shown in the μe experiments (see Figure 3), and it indicates that repulsive electric forces are the 
main factor responsible for the stability of the CS system at low ionic strength. Nevertheless, our 
deacetylated chitosan is a hydrophilic material, and therefore repulsive hydration forces should be 
expected to act under high-salinity conditions. This is why we immersed the CS particles in a pH 7.4 
buffer but previously adding a moderate or high NaCl concentration. It is worth highlighting that this 
saline-system was totally stable. This is why the CSC data shown in Table 2 for the CS-LNC were 
gathered from a high-salinity solution and making successive dilutions that reduced the ionic strength 
and, consequently, triggered coagulation at a given low-salinity value. 
In summary, the stability patterns of our systems comes from a combination of the destabilizing 
power exerted by salinity (which screens the electrical repulsion existing in low-ionic-strength media), 
and the stabilizing effect given by hydration forces in hydrophilic surfaces when salinity increases. 
When the electrolyte concentration is not too high (and hydration forces can be neglected), the CCC 
values correlate with the μe data in the less hydrophilic systems (EPI and CS), the stability being Int. J. Mol. Sci. 2012, 13                     
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governed mainly by the surface electrical charge (which in turn depends on the nature of the shell 
molecules).  For  high-salinity  conditions  or  for  highly  hydrophilic  surfaces  (i.e.,  PhS-LNC)  both 
repulsive steric and hydration forces keep stable the systems. 
With regard to the colloidal stability of our immuno-complexes, Figure 5 shows a typical experiment 
in which the stability factor (W) is evaluated at different CaCl2 concentrations. The W-stability factor is 
an experimental parameter that provides information on the coagulation probability: it is related to the 
number of collisions that two colliding particles must undergo before they remain definitively stuck. 
Therefore, W = 1 signifies a completely unstable system, while W = ∞ means total stability. The 
corresponding CCC values (calculated when W reduces to 1) are given in Table 2. These CCC data 
correlate properly with the mobility data at neutral pH (see Figure 3). The stability decreased when the 
IgG coating was increased. Although both systems presented quite low stability (CCC with CaCl2  
~10 mM), it was even lower when the IgG load was higher. It should be noted that the total stability 
found with the 1 mgIgG/m
2 system in NaCl solutions disappeared when the IgG coating increased up 
to 2.5 mgIgG/m
2. There is no doubt that the stability behavior of the PhS system significantly changed 
when the IgG molecules were linked to the bare PhS nanoparticles: A completely stable system in both 
salt solutions reduces its colloidal stability when protein molecules are bounded on its surface. This 
phenomenon  has  been  also  found  when  working  with  other  nanoparticles-protein  complexes  totally  
or  partially  covered  by  polyclonal  IgG  molecules  [28,33,45].  Beduneau  et  al.,  working  with  lipid 
nanocapsules conjugated with antibody molecules, detected an aggregation of the immuno-nanoparticles 
with a high density of antibodies [10], while Koning et al. detected the same stability when a high 
density of antibodies was grafted onto liposomes [34]. 
Figure 5. Stability factor vs. calcium chloride concentration (mM) at pH 7.4: (■) 1 mg/m
2 
IgG-PhS; (●) 2.5 mg/m
2 IgG-PhS. Solid lines help to locate the CCC values, while dashed 
lines point to the CSC data. 
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Once the stability was evaluated in simple pH 7.4 media, it was analyzed in the cell-culture medium 
(DMEM) supplemented with FBS, used to develop the in vitro uptake experiments in order to ensure 
that our different nanosystems preserve their colloidal stability in this complex medium. Figure 6 
shows the time evolution of optical absorbance when nanocapsules were introduced in the cell-culture 
medium. The absorbance remained constant, indicating that no aggregation took place. Taking into 
account the CSC values shown in Table 2, the high stability of all our LNC systems in this culture 
medium must be governed by the intrinsic hydrophilic character of their respective surfaces, since 
DMEM is a medium enriched with different cations that strengthen hydration forces enough to keep all 
of our nanoparticles stable. 
Figure 6. Aggregation kinetics of the (□) EPI; (○) CS; (∆) PhS; (■) PhS-1 mg/m
2 IgG;  
and (●) PhS-2.5 mg/m
2 IgG nanocapsules when immersed in DMEM medium supplemented 
with fetal bovine serum (FBS). 
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The  final  experiments  were  focused  on  analyzing  the  uptake  of  our  different  nanocapsules  by  a 
cancer-cell  line  (MCF -7).  To  quantify  this  cell  uptake,  we  worked  with  nanocapsules  loaded  by  Nile 
Red. The presence of Nile Red in the oily core of our nanoparticles was previously checked by means 
of  fluorescent  measurements.  It  should  be  noted  that  Nile  Red  presents  a  very  different  emission 
fluorescent  spectrum  as  a  function  of  the  medium  in  which  it  is  dissolved  [46].  Figure  7  shows  the 
emission fluorescent spectrum of the different nanoparticle systems. For all of them, the spectrum was 
similar  to  thos e  found  for  Nile  Red  dissolved  in  olive  oil.  Comparing  these  results  with  the  Nile  Red 
emission  spectrum  dissolved  in  an  aqueous  solution,  we  found  that  the  presence  of  this  fluorescent 
molecule in the hydrophobic oil core of our LCN was, therefore, clearl y confirmed. On the other hand, 
as expected, the encapsulation of Nile Red hardly changed the size or charge of LNC. Int. J. Mol. Sci. 2012, 13                     
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Figure  7.  Emission  spectrum  of  Red  Nile  in  olive  oil  and  water,  and  inside  different 
nanoparticles. (black line) EPI; (dashed line) CS; (dotted line) PhS; (dash-dot line) Olive 
oil; (gray line) water. 
 
The cell uptake of these fluorescent nanocapsules was analyzed by flow cytometric assays. Figure 8 
shows the fluorescence intensity of the cell cultures containing different nanosystems after 30 min and  
2 h of incubation time. The results led us to perform a quantitative analysis of the different nanocapsules, 
showing that the internalization efficacy was significantly changed by the nature and properties of the 
different shells. A combination of surface charge and hydrophilicity plays the major role in affinity in 
the endocytosis pathway [47]. Results with CS nanocapsules showed the highest fluorescent intensity, 
in agreement with the enhanced mucoadhesion properties reported for chitosan nanosystems [9,48]. 
The lower fluorescent response observed with the EPI and PhS systems appeared to be related both to 
the negative surface charge of these nanocapsules as well as to the hydrophilic character provided by 
poloxamer molecules—which produce more biocompatible systems but at the same time reducing their 
cellular uptake [10,49]. The higher hydrophilicity of the PhS surface (which presents an enriched 
Pluronic
® F68 layer according to the mobility and stability data) could be responsible for the low 
fluorescent intensity shown by these nanocapsules in comparison with the EPI ones. 
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Figure  8.  Relative  fluorescent  intensity  of  the  MCF7  cell  line  when  incubated  with  
Nile-Red-loaded  nanocapsules  for  30  min  and  2  h.  Control  refers  to  that  incubation 
performed only with cells. 
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Finally,  Figure  8  also  shows  an  increment  of  the  fluorescence  intensity  when  the  IgG  coverage 
increased.  Since  our  aCRP -IgG  molecules  did  not  recognize  any  specific  ligand  of  the  cell  membrane, 
a  change  in  the  cell  uptake  of  immuno -nanocapsules  with  regard  to  the  bare  nanocapsules  must  have 
been caused  by  both  the  surface  charge  and  hydrophilic  characteristics,  which  in  turn  were  modulated 
by  the  protein  coating.  Actually,  the  results  agree  with  the  surface  characteristics  discussed  above  for 
our  immuno-nanocapsules,  considering  their electrophoretic  and  stability behavior.  That  is,  the  electric 
charge  and  hydrophilic  character  decreased  when  the  amount  of  bounded  IgG  was  increased,  yielding 
to a situation in which the LNC endocytosis was enhanced. 
3. Experimental Section 
3.1. Reagents 
Olive oil, poloxamer 188 (Pluronic
® F68), Nile Red and phosphatidyl-L-serine were obtained from 
Sigma Aldrich. The olive oil was purified with activated magnesium silicate (Florisil, Fluka) in order to 
eliminate free fatty acids. Epikuron 145 V, which is a deoiled, wax-like, phosphatidyl-choline-enriched 
fraction  of  soybean  lecithin,  was  kindly  provided  by  CargilIbé rica  SL.  Protasan
®  Cl  113,  and  
medium-molecular-weight chitosan chloride salt with a deacetylation degree of 85%, was supplied from 
FMC Biopolymer Novamatrix (Norway). For the study of the electrophoretic mobility and colloidal 
stability at different pH values, several buffered solutions with a low ionic strength (I = 0.002 M) were 
prepared: pH 4 and 5 were buffered with acetate, pH 6 and 7 with phosphate, and pH 8 and 9 with borate. 
Additionally,  in  some  cases,  stability  was  evaluated  in  phosphate  buffer  saline  (PBS)  and  different 
culture mediums: Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with fetal bovine Int. J. Mol. Sci. 2012, 13                     
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serum. Other chemicals and electrolytes used were of analytical grade and purchased from Sigma, 
Merck, and Scharlau. Deionized Milli-Q water was used throughout. 
3.2. Nanocapsule Preparation 
The nanosystems studied were prepared by a solvent-displacement technique following the procedure 
of Prego et al. [50]. This is a well-known technique widely reported for the preparation of nanocapsules, 
where hydrophilic surfactants are usually dissolved in the aqueous phase before emulsion formation. 
Briefly, an organic phase was prepared containing 125 μL of olive oil and phospholipids: 40 mg of 
Epikuron 145 V (EPI nanocapsules) or 10 mg of phosphatidyl-L-serine (PhS nanocapsules) dissolved 
in 0.5 mL ethanol and 9.5 mL of acetone. This organic phase was immediately poured over an aqueous 
phase containing 50 mg of Pluronic
® F68 or 10 mg of chitosan oligomers. The mixture turned milky 
immediately because of the formation of the nanoemulsion. Then, the organic solvents were evaporated 
under vacuum to a final volume of 15 mL. Figure 9 shows a scheme of the synthesis procedure. All 
nanosystems presented olive oil in their hydrophobic core and, depending on the composition of the 
organic and aqueous phases, the final sample showed different interface properties. Thus, three different 
systems were formulated: EPI nanocapsules with a surface shell composed by epikuron and Pluronic
® 
F68;  CS nanocapsules with epikuron and chitosan oligomers; and finally,  PhS nanocapsules with 
phosphatidyl-L-serine and Pluronic
® F68. 
Figure 9. Scheme detailing the preparation of the particles. 
 
Fluorescent LNCs were formulated by dissolving Nile Red in the olive oil phase at a concentration 
of  0.025%  (w/w).  The  encapsulation  of  this  fluorescent  molecule  was  confirmed  by  using  a  SPEX 
Fluoromax-2 spectrofluorometer. The emission fluorescence spectra were determined from 550 to 700 nm 
previous excitation of the sample at a wavelength of 485 nm, with a scanning speed of 100 nm/min and 
a wavelength accuracy of ± 1 nm. Int. J. Mol. Sci. 2012, 13                     
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3.3. Nanocapsule Characterization 
3.3.1. Size, Morphology, and Storage Stability 
The average size of the nanosystems was determined by combining a high-performance-particle-sizer 
technology with a non-invasive-backscattering method, where the measurement is taken at an angle of 
173° . This technique minimizes multiple scattering [51] and the light detected is processed by a digital 
correlator (ALV 5000/E), providing information on the average diffusion coefficient of the particles, 
which can be easily related to the mean diameter (Ø) by using the Stokes-Einstein equation for spheres. 
The morphological characterization of the nanosystems was developed using transmission electron 
microscopy (TEM) in the Scientific Instrumentation Centre, Granada University (Spain). 
3.3.2. Electrophoretic Mobility 
A Zetasizer-nano (Malvern Instruments, UK) was used to measure the electrophoretic mobility (μe). 
The  study  was  focused  on  measuring  the  μe  as  a  function  of  pH  while  maintaining  a  constant  
low-ionic-strength value (0.002 M). Each μe mobility datum was the average of 6 individual measurements. 
3.3.3. Colloidal Stability 
Colloidal  stability  was  spectrophotometrically  studied  (Beckman  DU  7400  spectrophotometer) 
working at physiological pH in simple saline media. The salts used in these stability studies were NaCl 
and CaCl2. As described in detail in reference [52] and the supplementary materials, it is possible to 
derive the ―critical coagulation concentration‖ (CCC)  and  the ―critical stabilization concentration‖ 
(CSC) values. These parameters are fundamental in colloidal-stability studies, since they give valuable 
information about certain surface characteristics. For example, CCC is related to the surface charge 
density, while the CSC is associated to the surface hydrophilicity [51]. In addition to measuring the 
colloidal stability of our nanocapsules with NaCl and CaCl2, we also evaluated stability in PBS and in 
DMEM supplemented with fetal bovine serum by monitoring the variation of optical absorbance of the 
nanocapsules as a function of time. 
3.4. Immuno-Nanocapsules 
3.4.1. Conjugation of IgG Antibodies with LNC 
C-reactive  protein  (CRP)  and  polyclonal  immunoglobulin  G-anti-CRP  (aCRP-IgG)  from  rabbit 
were obtained, purified, and kindly donated by Biokit S.A. (Spain). The covalent attachment of aCRP-IgG 
to the PhS nanoparticles was performed according to the well-established carbodiimide method [27]. 
In this method, 1 ethyl-3-(3-dimethyl aminopropyl) carbodiimide (CDI) was used to bind the antibody 
via its amino groups to the carboxyl groups of the PhS nanoparticles. Briefly, a sample of PhS system 
having 0.2 m
2 of total surface was incubated at pH 8 with CDI (100 μL of a solution of 15 mg/mL) for 
30 min at 25 °C . Subsequently, activated nanoparticles were incubated with two different amounts of 
aCRP-IgG, 1 mg/m
2 and 2.5 mg/m
2, overnight. All the immuno-nanocapsules were cleaned by means 
of a dialysis process in pH 8 buffer solution in order to separate the non-coupled aCRP-IgG molecules. Int. J. Mol. Sci. 2012, 13                     
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3.4.2. Immunological Study 
The immunoassays were performed in saline BSA borate buffer: pH 8, borate (15 mM), NaCl  
(150  mM),  NaN3  as  preservative  (1  mg/mL),  and  bovine  serum  albumin  from  Sigma-Aldrich  
(1 mg/mL). The immuno-nanoparticles were diluted in this solution to provide a working LNC reagent. 
A series of CRP solutions was prepared in the saline BSA medium, the antigen concentration ranging 
from 0.25 µg/mL to 40 µ g/mL. Turbidimetric curves of absorbance vs. time were plotted using a 
simple spectrophotometer (Beckman DU 7400). Absorbance measurements were collected at 570 nm 
for 300 s at 25 °C , after mixing 50 μL of each antigen solution with 150 μL of the immuno-LNC solution. 
3.5. Cell Line and Culture Conditions 
A  breast-carcinoma  cell  line  (MCF-7)  was  supplied  by  the  Scientific  Instrumentation  Centre, 
Granada University (Spain). Cells were grown at 37 °C  in an atmosphere containing 5% CO2, with 
DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum  (FBS),  2%  L-glutamine,  2.7%  sodium  bicarbonate,  1%  Hepes  buffer,  and  1%  of 
penicillin/streptomycin solution. The intracellular uptake of fluorescence-labeled nanoparticles was 
performed  as  follows.  MCF-7  cells  (3  ×  10
4)  were  seeded  into  6-well  plates  under  the  culture 
conditions  detailed  above.  After  24  h,  cells  were  fed  with  fresh  medium  and  treated  with  
Nile-Red-nanocapsules. After incubation for 30 min and 2 h with particles labeled with Red Nile the 
cells  were  washed  with  PBS  to  remove  free  nanocapsules.  Then  the  cells  were  harvested  by  
PBS-ethylenediamine-tetraacetid acid (PBS-EDTA), washed twice with cold PBS, and pelleted by 
centrifugation at 1500 rpm for 5 min. Living cells were resuspended in PBS and analyzed for red 
fluorescence  by  flow  cytometry  in  a  FACScan  (Becton  Dickinson,  San  Jose,  CA,  USA).  The 
fluorescent pulses were analyzed by BD CellQuest Pro software [53]. Instrument settings, such as the 
photomultiplier  voltage  and  compensation,  were  adjusted  in  such  a  way  that  the  difference  in 
background fluorescence of cells without internalized nanocapsules became insignificant. SPSS [54] 
was used for the statistical analysis in cell culture studies. The results were compared by means of the 
Student’s t test. Differences were considered statistically significant at a p value of <0.05. 
4. Conclusions 
The present work constitutes basic research aimed mainly at analyzing certain surface characteristics 
(i.e., charge and hydrophilicity) of different lipid nanocapsules. Colloidal properties of a novel LNC 
system, in which the shell was enriched by carboxyl groups supplied by phosphatidyl-serine molecules, 
was compared to two standard LNC systems: an anionic one formed by Epikuron and Pluronic
® F68, 
and a cationic system coated by chitosan. Electrokinetic mobility and classical studies of colloidal 
stability lead us to conclude that the incorporation of Pluronic
® F68 on the PhS shell was higher than 
in  the  EPI  case.  Additionally,  the  original  PhS  surface  was  successfully  modified  by  linking 
(covalently) IgG molecules. The presence of these antibodies conferred specific recognition properties 
to these nanocapsules, showing clear binding of a specific antigen (CRP). In addition, the adhered 
antibody layer altered the original surface properties of the bare PhS particles, since both  surface 
charge  density  and  hydrophilicity  were  reduced  by  the  IgG  coating.  With  regard  to  the  cell-culture Int. J. Mol. Sci. 2012, 13                     
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incubation studies, all our systems were colloidally stable in the incubation medium thanks to the 
stabilizing role played by the hydration forces. The cellular uptake was modulated by the surface 
characteristics of the LNC, and the highest uptake was found with the CS cationic particles, while the 
lowest intracellular incorporation was found with the most hydrophilic negative surface (PhS). In the 
latter case a great amount of poloxamer molecules existed in the outer shell, hampering such uptake. In 
summary, we have developed a novel LNC system capable of linking antibodies by using a simple 
procedure yielding to active immuno-nanocapsules that may be useful for future potential applications 
in anti-cancer therapies. 
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